Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

COMBAT HBV Feasibility Trial (COMBAT-HBV)

22. oktober 2026 opdateret af: University of North Carolina, Chapel Hill

Forenkling af hepatitis B-pleje under graviditet ved at kombinere fødselsdosisvaccine og tenofovir: COMBAT HBV Feasibility Trial

This is a double-blind, randomized placebo-controlled trial (RCT) of a prophylaxis-for-all approach to prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in the Democratic Republic of Congo (DRC). HBV-infected pregnant women will be randomized to either receive tenofovir or placebo beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Women will be followed every 4-6 weeks throughout the prenatal and postpartum period to evaluate for side effects related to the medication. Infants will receive a birth-dose of HBV vaccine, ideally within 24 hours. Participants will be followed longitudinally through 6 months' postpartum.

Studieoversigt

Detaljeret beskrivelse

The overall study design is a randomized, double-blind, placebo-controlled trial among two groups of mother-infant dyads: women who receive TDF vs placebo in late pregnancy and the postpartum period (beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum). While official World Health Organization (WHO) recommendations are to continue TDF at least through delivery, a range from delivery through 12 weeks' postpartum is possible; the investigators will continue therapy through 4 weeks' postpartum in this study. This feasibility trial will evaluate the acceptability, safety and preliminary effectiveness of a TDF-for-all approach to prevent MTCT of HBV in low-resource settings. HBsAg-positive pregnant women will be enrolled at 28-32 weeks' gestation, and will present for regular medication checks, with a study closeout visit at 24 weeks' postpartum. Study activities at monthly medication checks will include medication refills, assessment of adherence (via pill counts and verbal surveys), and evaluation for side effects. All infants will receive a birth-dose of HBV vaccine within 24 hours of life. MTCT of HBV will be defined as the proportion of infants with positive HBsAg testing at 6 months. This pilot study will provide preliminary data for sample size calculations, including safety and effectiveness data, to prepare for larger RCTs to determine the effectiveness of a tenofovir-for-all approach, as well as the added benefit of tenofovir over birth-dose vaccination.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

315

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Pregnant women ≥18 years of age who present for routine prenatal care between 28-32 weeks' gestation and who test HBV-positive by point-of-care hepatitis B surface antigen test. Women must intend to seek maternity and postpartum care exclusively at one of the Kinshasa-based study maternity centers.
  • Infants born to enrolled women will be included in the study

Exclusion Criteria:

  • Individuals with abnormal creatinine by point-of-care testing
  • Any woman who plans to move outside of Kinshasa Province during the study period.
  • Any HIV-positive individual, determined by routine point-of-care screening at antenatal care visits

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Tenofovir disoproxil fumarate (TDF) arm

140 pregnant women in the experimental arm will receive tenofovir disoproxil fumarate (TDF) 300 milligrams (mg) daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.

Pregnant women in the experimental arm will receive TDF daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.

Andre navne:
  • Viread

All infants born to women in the study will receive a birth-dose hepatitis B vaccine.

Andre navne:
  • Engerix-B
  • Hepatitis B fødselsdosis vaccine
Placebo komparator: Placebo arm

140 pregnant women in the placebo arm will receive a placebo pill daily, beginning at 28-32 weeks' gestation and continuing through 4 weeks' postpartum. Infants born to these women will be included in this arm and will receive a birth-dose of hepatitis B vaccine.

All infants born to women in the study will receive a birth-dose hepatitis B vaccine.

Andre navne:
  • Engerix-B
  • Hepatitis B fødselsdosis vaccine

Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety (Pregnant Women): Number of Women With Adverse Effects Related to Study Medications
Tidsramme: Up to study close-out visit, or up to 6 months postpartum

Safety of TDF prophylaxis in pregnant women, defined as the number of participants who experienced at least one adverse event (# mild adverse events [AEs], # moderate-to-severe AEs and # life-threatening AEs) and/or alanine aminotransferase elevation ≥ 5x upper limit of normal

Up to study close-out visit, or up to 6 months postpartum
Safety (Infants): Number of Infants With Adverse Effects Related to Study Medications
Tidsramme: At delivery

Safety of hepatitis B birth-dose vaccine for infants, # of study medication related adverse events

At delivery
Feasibility (Recruitment): Number of Eligible Participants Who Were Enrolled in the Study
Tidsramme: Up to study close-out visit, or up to 6 months postpartum

Recruitment is indicative of the number of pregnant women who are screened versus those actually enrolled in the study.

Up to study close-out visit, or up to 6 months postpartum
Feasibility (Refusal): Number of Eligible Participants Who Refused to Enroll in the Study
Tidsramme: Screening until end of enrollment eligibility period, up to 32 weeks gestation

Refusal will be defined as the number of individuals who refuse enrollment upon initial recruitment.

Screening until end of enrollment eligibility period, up to 32 weeks gestation
Feasibility (Withdrawal): Number of Enrolled Participants Who Withdraw From the Study
Tidsramme: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)

Withdrawal is indicative of the number of enrolled participants who choose not to continue study activities after having been enrolled.

Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
Feasibility (Retention): Number of Enrolled Participants Who Remain in the Study Through 6 Months Postpartum
Tidsramme: Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)

Retention is defined as the number of participants who remain in the study through the 6-month postpartum visit.

Up to study close-out visit, or up to 6 months postpartum (Mothers) or up to 6 months of life (infants)
Feasibility (Maintenance): Mean Proportion of Study Visits Completed Per Maternal Participants
Tidsramme: Up to study close-out visit, or up to 6 months postpartum

Adherence to study visits and procedures among mothers, defined as the proportion of actual visits completed. The mean proportion of visits completed out of the total number of scheduled (or expected) study visits (i.e., up to eight possible visits) is reported.

Up to study close-out visit, or up to 6 months postpartum
Acceptability (Lab Testing): Number of Mothers With Lab Testing Acceptability Scores >80%
Tidsramme: Up to study close-out visit, or up to 6 months postpartum

Number of mothers who report the process of undergoing lab draws as "acceptable" in the exit survey. Range 0-100%, with 0% being unacceptable and 100% being acceptable.

Up to study close-out visit, or up to 6 months postpartum
Acceptability (Medication): Number of Mothers With Medication Acceptability Scores >80%
Tidsramme: Up to study close-out visit, or up to 6 months postpartum

Number of mothers who report the process of taking the study medication as "acceptable" in the exit survey. Range 0-100%, with 0% being unacceptable and 100% being acceptable.

Up to study close-out visit, or up to 6 months postpartum
Preliminary Effectiveness: Number of Infants With HBV Positivity by Rapid Diagnostic Testing at 6 Months of Life to Indicate Mother-to-Child Transmission of HBV
Tidsramme: Measured at 6 months after birth

Mother-to-child transmission of HBV is defined as HBsAg positivity in the infant at 6 months of life.

Measured at 6 months after birth

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sensitivity of the Hepatitis B Core-Related Antigen Test Among Maternal Participants
Tidsramme: Measured at Enrollment

Sensitivity will be defined as the number of true positive tests divided by the sum of the true positives and false negatives.

Measured at Enrollment
Specificity of the Hepatitis B Core-Related Antigen Test
Tidsramme: Measured at Enrollment

Specificity will be defined as the number of true negative tests divided by the sum of the true negatives and the false positives.

Measured at Enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Peyton Thompson, MD, MSCR, University of North Carolina, Chapel Hill

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. august 2023

Primær færdiggørelse (Faktiske)

25. november 2025

Studieafslutning (Faktiske)

25. november 2025

Datoer for studieregistrering

Først indsendt

20. januar 2023

Først indsendt, der opfyldte QC-kriterier

20. januar 2023

Først opslået (Faktiske)

30. januar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. oktober 2026

Sidst verificeret

1. februar 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Datasets will not be made publicly available because they contain protected health information. However, the authors will share de-identified participant data, alongside the study protocol, statistical analysis plan, and analytic code, upon reasonable request and with approval by an independent review committee (ie, learned intermediary). An executed Data Use/Sharing agreement with the University of North Carolina at Chapel Hill (UNC-CH) is required before data will be shared

IPD-delingstidsramme

Data will be available from 9 to 36 months after publication.

IPD-delingsadgangskriterier

Interested individuals can request de-identified data with approval from an independent review committee, which will be shared upon execution of a Data Use/Sharing Agreement with UNC-CH.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner